Especially, NfL has demonstrated utility as a prognostic biomarker in AD [317], PD [273], and ALS [275], with higher levels correlating with faster disease progression and higher rates of brain atrophy [315]. The gene discussed is NEFL; the disease is amyotrophic lateral sclerosis.